Aster lanza el trading de contratos perpetuos virtuales, con una capacidad de apalancamiento de hasta 75 veces.

• Aster has launched VIRTUAL perpetual contract trading with up to 75x leverage, allowing traders to earn 1.2x trading points during the promotional period according to Bitget.
• The platform reported a surge in trading volume, reaching $6.6 billion in 24-hour perpetual contract trading as reported.
• Yi Li Hua, founder of LD Capital, announced on X that he has exited his investment in Aster, citing difficulties in locating the project's founder according to Phemex.

Aster has introduced VIRTUAL perpetual contract trading with up to 75x leverage. This new offering enables traders to utilize high leverage for contract trading. During the promotional period from January 6th to January 13th 23:59 UTC, traders can earn 1.2x trading points according to Bitget.

The platform has seen a significant increase in trading activity, with a reported $6.6 billion in 24-hour perpetual contract trading volume. This development may attract increased trading activity and user engagement on the platform

as reported.

Yi Li Hua, founder of LD Capital, announced on X that he has exited his investment in Aster, citing difficulties in locating the project's founder. Despite expressing regret over the decision, Yi Li Hua remains optimistic about the future and expressed interest in supporting new exchange projects of a caliber similar to Binance according to Phemex.

Esco Aster, a Singapore-based CRDMO, announced CMC manufacturing support for Shine-On Biomedical's HLA-G targeted exosome program. The collaboration began in 2023, with Shine-On engaging Esco Aster for cGMP services, including high-yield exosome development using Esco Aster's proprietary cell line platform as reported.

Technical reports on process, analytical, and formulation development, exosome drug loading, GMP engineering runs, and stability studies supported Shine-On's IND submission, which was cleared by the U.S. FDA in Q1 2025 according to the announcement.

Shine-On's lead asset, SOB100, is a potential first-in-class HLA-G targeted exosome drug delivery carrier that has cleared FDA IND review and is undergoing a Phase I clinical study as detailed.

What is the significance of Aster's new trading feature?

Aster's launch of VIRTUAL perpetual contract trading with up to 75x leverage represents a strategic move to expand its trading options and attract leveraged traders. This feature allows traders to participate with higher leverage and potentially amplify their returns, which is particularly appealing in the volatile crypto market according to Bitget.

The promotional period, during which traders can earn 1.2x trading points, adds an incentive for new and existing users to engage with the platform. This could boost user engagement and trading activity, potentially increasing Aster's market share according to Bitget.

What is the impact of Yi Li Hua's exit on Aster?

Yi Li Hua's exit from his investment in Aster raises questions about the project's leadership and management. His decision to leave was influenced by difficulties in locating the project's founder, which could affect investor confidence and the platform's reputation according to Phemex.

Despite the exit, Yi Li Hua expressed optimism about the future and interest in supporting new exchange projects. This suggests that while there may be short-term concerns, the broader market remains interested in innovative crypto exchanges according to Phemex.

What is the role of Esco Aster in the exosome drug delivery platform?

Esco Aster played a crucial role in supporting Shine-On Biomedical's IND submission by providing high-yield exosome development services and GMP engineering runs. This collaboration highlights Esco Aster's expertise in exosome manufacturing and its contribution to advancing Singapore's biotechnology sector as reported.

The partnership between Esco Aster and Shine-On Biomedical is significant as it demonstrates the potential of exosome-based drug delivery platforms. Shine-On's lead asset, SOB100, has shown promise in preclinical studies and is now in a Phase I clinical trial, indicating a strong foundation for future development according to the announcement.

Esco Aster continues to support Shine-On with exploratory exosome loading feasibility studies, ensuring the platform remains flexible as clinical data evolves. This collaboration reinforces Esco Aster's position as a leader in exosome development and GMP manufacturing in Singapore as detailed.